Sweden Cancer Pain Management Market Report 2022 to 2030

Sweden Cancer Pain Management Market Analysis

$ 3999

Sweden's Cancer Pain Management market is projected to grow from $23.47 Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The main factors driving the growth would be a high standard of healthcare, a high prevalence of cancer cases, and investment in research and development. The market is segmented by drug type and by disease. Some of the major players include Orexo (SWE), Meda pharmaceuticals (SWE), Grunenthal Pharma, Mundipharma, Pfizer, and Teva Pharmaceuticals.

ID: IN10SEHS002 CATEGORY: Healthcare Services GEOGRAPHY: Sweden AUTHOR: Neha Davda

Buy Now

Sweden Cancer Pain Management Market Executive Summary

Sweden's Cancer Pain Management market is projected to grow from $23.47 Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The majority of the money for health spending in Sweden comes from local taxes, direct transfers from the national government, subsidies to the regions for outpatient pharmaceuticals, and certain national programs. Sweden placed third among EU countries in terms of health spending in 2019, spending 10.9% of GDP on it, more than the EU average of 9.9%.

Cancer pain may be brought on by cancer itself, or it may be brought on by procedures like chemotherapy and surgery that are connected with it. The choice of drugs and how they are used depends on the kind, location, and intensity of the pain being experienced. In order to control cancer pain, many different medications are used. Strong opioids, for example, are used more frequently to treat severe pain, but acetaminophen and NSAIDs, which are non-opioids, are used more frequently to treat mild to moderate cancer pain. Europe is one of the established players in the world market for cancer pain management, and it is also home to some of the top pharmaceutical companies engaged in the research and development of new pain management drugs.

Market Dynamics

Market Growth Drivers

The Sweden cancer pain management market is expected to be driven by factors such as a high standard of healthcare and investment in research and development. Also, Sweden has a relatively high prevalence of cancer, which has increased the need for efficient methods of pain management.

Market Restraints

Adverse side effects of pain management drugs and the competition of branded medicine with less expensive medicines will restrain the growth of cancer pain management in Sweden.

Competitive Landscape

Key Players

Orexo (SWE)
Meda pharmaceuticals (SWE)
Grunenthal Pharma
Mundipharma
Pfizer
Teva Pharmaceuticals

Notable Recent Deals

January 2020: Mundipharma announced a partnership with Samsung Bioepis to market Samsung Bioepis' initial batch of biosimilar candidates in Taiwan and Hong Kong. The agreement covers the biosimilar candidates from Samsung Bioepis in the fields of immunology and oncology, including SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab), and SB8 (bevacizumab).

Healthcare Policies and Regulatory Landscape

Sweden has a highly developed healthcare system, favorable reimbursement rules, and a strict regulatory landscape for medicines and medical equipment, all of which promote market growth for cancer pain management. All inhabitants in Sweden have access to medical care, including pain management, thanks to the country's universal healthcare system.

The main regulatory organization in charge of regulating healthcare in Sweden and making sure that medical services are safe and of high quality is the Swedish National Board of Health and Welfare. This entails establishing requirements for methods of pain management, approving fresh medications and medical equipment, and controlling how these therapies are applied. New medications and medical equipment must be evaluated and approved for use in Sweden by the Swedish Medical Products Agency.

Reimbursement Scenario

Sweden's reimbursement policy for the pain management market is advantageous, with a focus on ensuring that all people have access to medical care and services. The Swedish Social Insurance Agency is in charge of carrying out the policies governing the payment for medical services, including procedures for pain management. The majority of medical services, including pain management therapies, are paid for by the government and provided at no cost to patients under Sweden's system of universal healthcare coverage. Patients may occasionally be required to pay out a modest sum for specific treatments, such as prescription medications. These costs, meanwhile, are often low and do not significantly impede access.

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cancer Pain Management Market Segmentation

By Drug Type (Revenue, USD Billion):

Non-steroidal anti-inflammatory medicines relieve pain at the site of injury by blocking the cyclooxygenase enzyme, which prevents prostaglandin formation. NSAIDs are a class of medications that includes medications with analgesic, antipyretic, and, at higher doses, anti-inflammatory properties.

Opioids
Morphine
- Fentanyl
- Others
Non-Opioids
Acetaminophen
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Nerve Blockers

By Disease Indication (Revenue, USD Billion):

Based on disease Indication the market is segmented into:

Lung Cancer
Colorectal cancer
Breast cancer
Prostate cancer
Blood cancer
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.